Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Director | February 14, 2021 | February 18, 2021 |
| Aravive, Inc.VSAR · Entity 114535 | Director | December 20, 2017 | December 22, 2017 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | November 10, 2023 | November 14, 2023 |
| Jade Biosciences, Inc.JBIO · Entity 4757 | Director | June 09, 2026 | June 11, 2026 |
| Janux Therapeutics, Inc.JANX · Entity 4864 | Director | June 11, 2026 | June 13, 2026 |
| STEMLINE THERAPEUTICS INCSTML · Entity 148550 | Director | June 19, 2017 | June 20, 2017 |
| Seagen Inc.SGEN · Entity 13956 | Chief Operating Officer | December 04, 2017 | December 06, 2017 |
| Structure Therapeutics Inc.GPCR · Entity 1222 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date February 14, 2021 · Filed February 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,504 |
Reported balance
After 2021-02-14 transaction · row 1
1 source rowRow 1 · 2021-02-14 · Grant · Acquired 1,504 · Balance 1,504 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.50 · Expires 2031-02-14 | Direct | 3,759 |
Reported balance
After 2021-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-14 · Grant · Acquired 3,759 · Balance 3,759 F1: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date.
Aravive, Inc.
Report date December 20, 2017 · Filed December 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,160 |
Reported balance
After 2017-12-20 transaction · row 1
1 source rowRow 1 · 2017-12-20 · Grant · Acquired 11,200 · Balance 18,160 F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018.
Atara Biotherapeutics, Inc.
Report date November 10, 2023 · Filed November 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 563,325 |
Reported balance
After 2023-11-10 transaction · row 1
1 source rowRow 1 · 2023-11-10 · Purchase · Acquired 446,825 · Balance 563,325 F1: Represents the weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $0.2235 to $0.2298. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $0.2235 to $0.2298. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
Jade Biosciences, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.22 · Expires 2036-06-08 | Direct | 34,843 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 34,843 · Balance 34,843 F1: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.
Janux Therapeutics, Inc.
Report date June 11, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,481 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,500 · Balance 15,481 F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.66 · Expires 2036-06-10 | Direct | 15,500 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 15,500 · Balance 15,500 F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.
STEMLINE THERAPEUTICS INC
Report date June 19, 2017 · Filed June 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,963 |
Reported balance
After 2017-06-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-06-19 · Grant · Acquired 10,000 · Balance 27,963 F1: The restricted shares will vest according to the following schedule: 3,334 shares on 6/19/2018, 3,333 shares on 6/19/2019 and 3,333 shares on 6/19/2020. F2: Of the 27,963 shares, 16,666 shares are restricted stock. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2027-06-19 | Direct | 24,000 |
Reported balance
After 2017-06-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-19 · Grant · Acquired 24,000 · Balance 24,000 F3: The options will vest according to the following schedule: one-third on each of 6/19/2018, 6/19/2019, and 6/19/2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted shares will vest according to the following schedule: 3,334 shares on 6/19/2018, 3,333 shares on 6/19/2019 and 3,333 shares on 6/19/2020.
F2: Of the 27,963 shares, 16,666 shares are restricted stock.
F3: The options will vest according to the following schedule: one-third on each of 6/19/2018, 6/19/2019, and 6/19/2020.
Seagen Inc.
Report date December 04, 2017 · Filed December 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 119,860 |
Last balance in matching sequence
After 2017-12-04 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2017-12-04 · Exercise / conversion · Acquired 3,729 · Balance 121,153 F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Row 2 · 2017-12-04 · Sale · Disposed 3,729 · Balance 117,424 F2: Reflects sales of common stock executed in multiple transactions at prices ranging from $58.53 to $58.85. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Row 3 · 2017-12-04 · Exercise / conversion · Acquired 2,436 · Balance 119,860 F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.04 · Expires 2023-08-19 | Direct | 0 |
Reported balance
After 2017-12-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-12-04 · Exercise / conversion · Disposed 2,436 · Balance 0 F3: Shares vested at a rate of 25% on 8/19/14 and monthly thereafter until all the shares were fully vested on 8/19/17. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.10 · Expires 2022-08-20 | Direct | 24,700 |
Reported balance
After 2017-12-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-12-04 · Exercise / conversion · Disposed 3,729 · Balance 24,700 F4: Shares vested at a rate of 25% on 8/20/13 and monthly thereafter until all the shares were fully vested on 8/20/16. |
Filing footnotes · ownership attribution and instrument terms
F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
F2: Reflects sales of common stock executed in multiple transactions at prices ranging from $58.53 to $58.85. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3: Shares vested at a rate of 25% on 8/19/14 and monthly thereafter until all the shares were fully vested on 8/19/17.
F4: Shares vested at a rate of 25% on 8/20/13 and monthly thereafter until all the shares were fully vested on 8/20/16.
Structure Therapeutics Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-06-16 | Direct | 39,453 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 39,453 · Balance 39,453 F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,
F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHINOOK THERAPEUTICS, INC.
Report date August 11, 2023 · Filed August 11, 2023
Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 301,138 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2029-06-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 353,358 · Balance 0 F2: This stock option award, which provided for 25% of the award to vest on April 1, 2020 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2030-03-17 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 313,555 · Balance 0 F3: This stock option award, which provided for 25% of the award to vest on March 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-11 · Disposition to issuer · Disposed 271,647 · Balance 0 F4: This stock option award, which provided for 25% of the award to vest on October 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.14 · Expires 2031-02-09 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-11 · Disposition to issuer · Disposed 178,600 · Balance 0 F5: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.90 · Expires 2032-01-30 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-11 · Disposition to issuer · Disposed 300,000 · Balance 0 F6: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.27 · Expires 2033-01-30 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-08-11 · Disposition to issuer · Disposed 255,150 · Balance 0 F7: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-08-11 · Disposition to issuer · Disposed 30,797 · Balance 0 F8: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F9: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-08-11 · Disposition to issuer · Disposed 20,248 · Balance 0 F8: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-08-11 · Disposition to issuer · Disposed 50,001 · Balance 0 F8: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-08-11 · Disposition to issuer · Disposed 64,050 · Balance 0 F8: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F12: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-08-11 · Disposition to issuer · Disposed 11,300 · Balance 0 F8: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F13: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
F2: This stock option award, which provided for 25% of the award to vest on April 1, 2020 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F3: This stock option award, which provided for 25% of the award to vest on March 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F4: This stock option award, which provided for 25% of the award to vest on October 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F5: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F6: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F7: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F8: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F9: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F12: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
F13: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2020 Filed Jul 9, 2020 00:28 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-041832 · doc4.xml · derivative · entry 4 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 10,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 00:28 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 400 | $47.98 | $19,192.00 |
DisclosureSEC source: 0001209191-20-041832 · doc4.xml · nonDerivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.83 to 48.42, inclusive. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 00:28 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 9,600 | $47.34 | $454,464.00 |
DisclosureSEC source: 0001209191-20-041832 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.80 to 47.70, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 00:28 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 10,000 | $6.32 | $63,200.00 |
DisclosureSEC source: 0001209191-20-041832 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 21:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 24,500 | $0.00 Strike: $10.54 | $0.00 |
DisclosureSEC source: 0001209191-20-037365 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2030-06-15 F2 · derivative.exercise_date: The option shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 21:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037365 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · shares: These restricted stock units shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 03, 2020 Filed Jun 6, 2020 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-034878 · doc4.xml · derivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 5,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 03, 2020 Filed Jun 6, 2020 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,000 | $39.79 | $198,950.00 |
DisclosureSEC source: 0001209191-20-034878 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 03, 2020 Filed Jun 6, 2020 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 5,000 | $6.32 | $31,600.00 |
DisclosureSEC source: 0001209191-20-034878 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2020 Filed May 22, 2020 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-031538 · doc4.xml · derivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 5,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. F2 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 19, 2020 Filed May 22, 2020 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,000 | $40.00 | $200,000.00 |
DisclosureSEC source: 0001209191-20-031538 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| May 19, 2020 Filed May 22, 2020 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 5,000 | $6.32 | $31,600.00 |
DisclosureSEC source: 0001209191-20-031538 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| May 07, 2020 Filed May 9, 2020 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-028108 · doc4.xml · derivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 5,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. F2 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 07, 2020 Filed May 9, 2020 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,000 | $35.00 | $175,000.00 |
DisclosureSEC source: 0001209191-20-028108 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| May 07, 2020 Filed May 9, 2020 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 5,000 | $6.32 | $31,600.00 |
DisclosureSEC source: 0001209191-20-028108 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009858 · doc4.xml · derivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-000884 · doc4.xml · derivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 5,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. F2 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Disposition to issuerCommon Stock | 5,000 | $30.00 | $150,000.00 |
DisclosureSEC source: 0001209191-20-000884 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 5,000 | $6.32 | $31,600.00 |
DisclosureSEC source: 0001209191-20-000884 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| December 31, 2019 Filed Jan 8, 2020 02:00 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-002421 · doc4a.xml · derivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 5,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. F2 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 31, 2019 Filed Jan 8, 2020 02:00 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,000 | $30.00 | $150,000.00 |
DisclosureSEC source: 0001209191-20-002421 · doc4a.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| December 31, 2019 Filed Jan 8, 2020 02:00 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 5,000 | $6.32 | $31,600.00 |
DisclosureSEC source: 0001209191-20-002421 · doc4a.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| December 26, 2019 Filed Dec 30, 2019 21:14 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-19-062109 · doc4.xml · derivative · entry 4 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 15,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. F3 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 26, 2019 Filed Dec 30, 2019 21:14 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Disposition to issuerCommon Stock | 2 | $29.91 | $59.82 |
DisclosureSEC source: 0001209191-19-062109 · doc4.xml · nonDerivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| December 26, 2019 Filed Dec 30, 2019 21:14 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Disposition to issuerCommon Stock | 14,998 | $29.29 | $439,291.42 |
DisclosureSEC source: 0001209191-19-062109 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $28.85 to 29.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 26, 2019 Filed Dec 30, 2019 21:14 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-19-062109 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| December 26, 2019 Filed Jan 8, 2020 02:00 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-002418 · doc4a.xml · derivative · entry 4 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 15,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. F3 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 26, 2019 Filed Jan 8, 2020 02:00 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2 | $29.91 | $59.82 |
DisclosureSEC source: 0001209191-20-002418 · doc4a.xml · nonDerivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| December 26, 2019 Filed Jan 8, 2020 02:00 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 14,998 | $29.29 | $439,291.42 |
DisclosureSEC source: 0001209191-20-002418 · doc4a.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $28.85 to 29.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 26, 2019 Filed Jan 8, 2020 02:00 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-20-002418 · doc4a.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 21:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $20.25 | $0.00 |
DisclosureSEC source: 0001209191-19-039770 · doc4.xml · derivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-26 F2 · derivative.exercise_date: The option shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 21:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039770 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: These restricted stock units shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 21:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | PurchaseCommon Stock | 2,000 | $19.50 | $39,000.00 |
DisclosureSEC source: 0001209191-19-039770 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-18-038300 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-06-13 F2 · derivative.exercise_date: The option shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038300 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · shares: These restricted stock units shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 21:59 UTC | Aravive, Inc. VSAR · Entity 114535 | GrantCommon Stock | 11,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067086 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,160 F1 · shares: Represents the grant of restricted stock units that vest 100% on December 20, 2018. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 20:04 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,729 | $0.00 Strike: $26.10 | $0.00 |
DisclosureSEC source: 0001203311-17-000096 · edgardoc.xml · derivative · entry 5 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,700 Underlying: Common Stock · 3,729 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares vested at a rate of 25% on 8/20/13 and monthly thereafter until all the shares were fully vested on 8/20/16. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 20:04 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,436 | $0.00 Strike: $41.04 | $0.00 |
DisclosureSEC source: 0001203311-17-000096 · edgardoc.xml · derivative · entry 4 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,436 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares vested at a rate of 25% on 8/19/14 and monthly thereafter until all the shares were fully vested on 8/19/17. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 20:04 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 2,436 | $41.04 | $99,973.44 |
DisclosureSEC source: 0001203311-17-000096 · edgardoc.xml · nonDerivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 20:04 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 3,729 | $58.75 | $219,091.80 |
DisclosureSEC source: 0001203311-17-000096 · edgardoc.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,424 F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $58.53 to $58.85. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 20:04 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 3,729 | $26.10 | $97,326.90 |
DisclosureSEC source: 0001203311-17-000096 · edgardoc.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 20:45 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.10 | $0.00 |
DisclosureSEC source: 0001203311-17-000090 · edgardoc.xml · derivative · entry 12 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,429 Underlying: Common Stock · 10,000 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Shares vested at a rate of 25% on 8/20/13 and monthly thereafter until all the shares were fully vested on 8/20/16. Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 20:45 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 10,000 | $59.13 | $591,250.00 |
DisclosureSEC source: 0001203311-17-000090 · edgardoc.xml · nonDerivative · entry 8 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,424 F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $59.00 to $59.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 20:45 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 10,000 | $26.10 | $261,000.00 |
DisclosureSEC source: 0001203311-17-000090 · edgardoc.xml · nonDerivative · entry 7 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 20:45 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,911 | $0.00 Strike: $26.10 | $0.00 |
DisclosureSEC source: 0001203311-17-000090 · edgardoc.xml · derivative · entry 11 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,429 Underlying: Common Stock · 6,911 shares Expires 2022-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Shares vested at a rate of 25% on 8/20/13 and monthly thereafter until all the shares were fully vested on 8/20/16. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 20:45 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,489 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001203311-17-000090 · edgardoc.xml · derivative · entry 10 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,489 shares Expires 2021-08-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Shares vested at a rate of 25% on 8/24/12 and monthly thereafter until all the shares were fully vested on 8/24/15. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 20:45 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 8,489 | $57.95 | $491,937.55 |
DisclosureSEC source: 0001203311-17-000090 · edgardoc.xml · nonDerivative · entry 6 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,424 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 20:45 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 8,489 | $15.46 | $131,239.94 |
DisclosureSEC source: 0001203311-17-000090 · edgardoc.xml · nonDerivative · entry 5 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 20:45 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 6,911 | $57.98 | $400,699.78 |
DisclosureSEC source: 0001203311-17-000090 · edgardoc.xml · nonDerivative · entry 4 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,424 F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $57.95 to $58.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 20:45 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 6,911 | $26.10 | $180,377.10 |
DisclosureSEC source: 0001203311-17-000090 · edgardoc.xml · nonDerivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.